Alimera Sciences' ILUVIEN(R) receives marketing authorization in Finland and Luxembourg
Alimera Sciences announced that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN® for treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. January 26, 2015